← boardnext 2026-08next 2027-12-31
GIKLY
Grifols Therapeutics LLCdistress 0/10 · well-funded / low risk$5.100%today-32% from 52w high
Oncology 1
Lead: Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency
Revenue
$1700M
Liquidity
$1367M
Runway
—
Shares 1y
—
Price & events
-16.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
-9.5%
1M
-10.3%
3M
-16.4%
6M
-26.0%
1Y
+2.9%
2Y
-57.0%
5Y
-65.7%
All
Overview
- Volume
- 0
- 52 Week Range
- $5.06 – $7.49
- Float Shares
- 836.24M
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 0.00%
- Beta
- 1.18
Pipeline stages · 3 programs
Alpha-1 MP
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Gamunex-C, Xembify
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Xembify, Placebo
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 5 trials · 4 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08 Estimated 50% readout ~2026-10-15 final ~2027-08-01 | Phase 3 | Alpha-1 MP | Pulmonary Emphysema in Alpha-1 PI Deficiency | — | active not recruiting |
| 2027-09-30 Estimated 50% readout ~2027-12-14 | Phase 3 | Alpha-1 15% | Alpha 1 Antitrypsin Deficiency | — | recruiting |
| 2027-12-31 Estimated 50% readout ~2028-03-15 | Phase 3 | Gamunex-C, Xembify | CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) | — | recruiting |
| 2028-09 Estimated 50% readout ~2028-11-15 | Phase 3 | Alpha-1 MP | Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency | — | enrolling by invitation |
| 2026-05 | Phase 3 | Xembify, Placebo | Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia, Multiple Myleoma, Non-Hodgkin Lymphoma | 386 | recruiting |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: — · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency
- none identified
Recent news
- 2026-07-22Grifols stock trades steady as debt reduction and margin recovery shape investor focus - Ad-hoc-news.de
- 2026-07-18Grifols stock holds focus as 2025 results frame the next move - Ad-hoc-news.de
- 2026-07-17Grifols stock trades around recent lows as leverage and governance remain under scrutiny - Ad-hoc-news.de
- 2026-07-16Grifols Trial Could Expand Treatment Options for 60,000 Patients - Stock Titan
- 2026-07-13Grifols, S.A. (GRFS) Stock Analysis: Exploring a Potential 49.45% Upside for Healthcare Investors - DirectorsTalk Interviews
- 2026-07-10Grifols deaths and harm: Patient safety & options for accountability - Yahoo Finance
- 2026-07-09Grifols navigates plasma demand and debt strategy as global healthcare needs grow - Ad-hoc-news.de
- 2026-07-09Grifols SA outlines plasma strategy as investors weigh long-term growth - Ad-hoc-news.de
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.